全文获取类型
收费全文 | 2557篇 |
免费 | 203篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 170篇 |
妇产科学 | 18篇 |
基础医学 | 241篇 |
口腔科学 | 76篇 |
临床医学 | 307篇 |
内科学 | 559篇 |
皮肤病学 | 47篇 |
神经病学 | 185篇 |
特种医学 | 296篇 |
外科学 | 276篇 |
综合类 | 70篇 |
预防医学 | 198篇 |
眼科学 | 60篇 |
药学 | 138篇 |
中国医学 | 6篇 |
肿瘤学 | 121篇 |
出版年
2023年 | 12篇 |
2021年 | 31篇 |
2020年 | 13篇 |
2019年 | 17篇 |
2018年 | 52篇 |
2017年 | 25篇 |
2016年 | 33篇 |
2015年 | 47篇 |
2014年 | 50篇 |
2013年 | 69篇 |
2012年 | 99篇 |
2011年 | 91篇 |
2010年 | 69篇 |
2009年 | 89篇 |
2008年 | 116篇 |
2007年 | 102篇 |
2006年 | 117篇 |
2005年 | 74篇 |
2004年 | 87篇 |
2003年 | 104篇 |
2002年 | 88篇 |
2001年 | 82篇 |
2000年 | 70篇 |
1999年 | 65篇 |
1998年 | 70篇 |
1997年 | 68篇 |
1996年 | 76篇 |
1995年 | 52篇 |
1994年 | 53篇 |
1993年 | 62篇 |
1992年 | 54篇 |
1991年 | 50篇 |
1990年 | 52篇 |
1989年 | 87篇 |
1988年 | 68篇 |
1987年 | 72篇 |
1986年 | 70篇 |
1985年 | 51篇 |
1984年 | 31篇 |
1983年 | 28篇 |
1982年 | 28篇 |
1981年 | 19篇 |
1980年 | 15篇 |
1979年 | 10篇 |
1978年 | 10篇 |
1977年 | 17篇 |
1976年 | 15篇 |
1975年 | 20篇 |
1969年 | 18篇 |
1968年 | 9篇 |
排序方式: 共有2774条查询结果,搜索用时 15 毫秒
1.
Isolation of Stomatococcus mucilaginosus from drug user with endocarditis. 总被引:4,自引:4,他引:0
下载免费PDF全文
![点击此处可从《Journal of clinical microbiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
P E Coudron S M Markowitz L B Mohanty P F Schatzki J M Payne 《Journal of clinical microbiology》1987,25(8):1359-1363
Stomatococcus mucilaginosus was isolated from the blood of a patient with endocarditis and a past history of drug abuse and aortic valve replacement. At autopsy, Gram stain of the aortic valve revealed gram-positive cocci. Our isolate was atypical for S. mucilaginosus in that colonies were nonmucoid and nonadherent to agar surfaces. Cellular capsules were demonstrated by light and electron microscopy. Phenotypic characteristics identified by conventional methods as well as profile numbers obtained by using two commercial identification systems for staphylococci, the API Staph-Ident and the dms Staph Trac, are presented. Practical tests that differentiate S. mucilaginosus from the genera Micrococcus and Staphylococcus include growth on nutrient agar containing salt and lysostaphin susceptibility. Additional tests that helped differentiate our isolate from group D streptococci included hydrolysis of L-pyrrolidonyl-beta-naphthylamide and streptococcal serogrouping. 相似文献
2.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
3.
4.
5.
6.
The aromatic amine ortho-toluidine has been recognized by IARC as an animal carcinogen for the past decade. Three recent epidemiological studies of worker populations have now implicated this chemical as a human bladder carcinogen. In a study by E. Ward, A. Carpenter, S. Markowitz, D. Roberts, and W. Halperin ((1991), J. Natl. Cancer Inst. 83, 501–506), workers definitely exposed to ortho-toluidine for at least 10 years experienced a Standardized Incidence Ratio (SIR) of 27.2 (90% CI = 11.8–53.7). The other major exposure was to aniline, which significant epidemiological studies have failed to confirm as a human carcinogen. In retrospect, studies by G. F. Rubino, G. Scansetti, G. Piolatto ((1982) Environ. Res. 27, 241–254) and M. J. Stasik ((1988) Int. Arch. Occup. Environ. Health 60, 21–24) also support the hypothesis that ortho-toluidine is a human bladder carcinogen. Animal studies of both ortho-toluidine and its possible confounders in these epidemiological investigations further confirm this hypothesis. When evaluated in a suitably comprehensive way, according to the traditional standards for assessing causality outlined by A. B. Hill ((1977) A Short Textbook of Medical Statistics, pp. 288–294, Lippincott, Philadelphia) the evidence that ortho-toluidine causes human bladder cancer has become much more conclusive. In this case, animal tests have proven a good predictor of human carcinogenicity. 相似文献
7.
8.
9.
10.